The DOI matches its Crossref record; 410 of the 410 references it cites were found in a registry or an index.
EGFR signaling pathway as therapeutic target in human cancers
Open accessAbstract
Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand orchestrator of epithelial transformation, and hence one of the most world-wide studied tyrosine kinase receptors involved in neoplasia, in several tissues. In the last decades, EGFR-targeted therapies shaped the new era of precision-oncology. Despite major advances, the dream of converting solid tumors into a chronic disease is still unfulfilled, and long-term remission eludes us. Studies investigating the function of this protein in solid malignancies have revealed numerous ways how tumor cells dysregulate EGFR function. Starting from preclinical models (cell lines, organoids, murine models) and validating in clinical specimens, EGFR-related oncogenic pathways, mechanisms of resistance, and novel avenues to inhibit tumor growth and metastatic spread enriching the therapeutic portfolios, were identified. Focusing on non-small cell lung cancer (NSCLC), where EGFR mutations are major players in the adenocarcinoma subtype, we will go over the most relevant discoveries that led us to understand EGFR and beyond, and highlight how they revolutionized cancer treatment by expanding the therapeutic arsenal at our disposal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–400 of 410
Wang, S.-C., & Hung, M.-C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2813 · Cited by 190
Gao, R. W., Teraphongphom, N., de Boer, E., Berg, N. S. V. D., Divi, V., Kaplan, M. J., Oberhelman, N. J., Hong, S. S., Capes, E., Colevas, A. D., et al. (2018) · Theranostics · doi:10.7150/thno.24487 · Cited by 190
Gonzalvez, F., Vincent, S., Baker, T. E., Gould, A. E., Li, S., Wardwell, S. D., Nadworny, S., Ning, Y., Zhang, S., Huang, W.-S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1683 · Cited by 190
Co‐regulation of B‐Myb expression by E2F1 and EGF receptor
Hanada, N., Lo, H., Day, C., Pan, Y., Nakajima, Y., & Hung, M. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20147 · Cited by 188
Zhao, Y., Harrison, D. L., Song, Y., Ji, J., Huang, J., & Hui, E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.054 · Cited by 188
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Ali, A., Levantini, E., Teo, J. T., Goggi, J., Clohessy, J. G., Wu, C. S., Chen, L., Yang, H., Krishnan, I., Kocher, O., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708313 · Cited by 187
Self-citationLo, H.-W., Cao, X., Zhu, H., & Ali-Osman, F. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0391 · Cited by 186
Epidermal Growth Factor Receptor Translocation to the Mitochondria
Demory, M. L., Boerner, J. L., Davidson, R., Faust, W., Miyake, T., Lee, I., Hüttemann, M., Douglas, R., Haddad, G., & Parsons, S. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000760 · Cited by 184
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
Tu, H.-Y., Ke, E.-E., Yang, J.-J., Sun, Y.-L., Yan, H.-H., Zheng, M.-Y., Bai, X.-Y., Wang, Z., Su, J., Chen, Z.-H., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.005 · Cited by 182
Irwin, M. E., Mueller, K. L., Bohin, N., Ge, Y., & Boerner, J. L. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22570 · Cited by 181
Targeted radionuclide therapy in combined-modality regimens
Gill, M. R., Falzone, N., Du, Y., & Vallis, K. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30379-0 · Cited by 181
Bjorge, J. D., Chan, T. O., Antczak, M., Kung, H. J., & Fujita, D. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.10.3816 · Cited by 180
Akamatsu, H., Toi, Y., Hayashi, H., Fujimoto, D., Tachihara, M., Furuya, N., Otani, S., Shimizu, J., Katakami, N., Azuma, K., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6758 · Cited by 179
Rowinsky, E. K. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104433 · Cited by 178
Li, B., Ren, S., Li, X., Wang, Y., Garfield, D., Zhou, S., Chen, X., Su, C., Chen, M., Kuang, P., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.003 · Cited by 177
Nukaga, S., Yasuda, H., Tsuchihara, K., Hamamoto, J., Masuzawa, K., Kawada, I., Naoki, K., Matsumoto, S., Mimaki, S., Ikemura, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2359 · Cited by 175
Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.
Uramoto, H., Iwata, T., Onitsuka, T., Shimokawa, H., Hanagiri, T., & Oyama, T. (2010) · PubMed · Cited by 171
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Pollack, B. P., Sapkota, B., & Cartee, T. V. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3283 · Cited by 169
Engelhardt, H., Böse, D., Petronczki, M. P., Scharn, D., Bader, G., Baum, A., Bergner, A., Chong, E., Döbel, S., Egger, G., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01169 · Cited by 169
Madshus, I. H., & Stang, E. (2009) · Journal of Cell Science · doi:10.1242/jcs.050260 · Cited by 167
Takeda, M., & Nakagawa, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010146 · Cited by 167
Möhrmann, L., Huang, H. J., Hong, D. S., Tsimberidou, A. M., Fu, S., Piha-Paul, S. A., Subbiah, V., Karp, D. D., Naing, A., Krug, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2007 · Cited by 166
Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
Zhang, T., Wan, B., Zhao, Y., Li, C., Liu, H., Lv, T., Zhan, P., & Song, Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.12 · Cited by 166
Hirano, T., Yasuda, H., Tani, T., Hamamoto, J., Oashi, A., Ishioka, K., Arai, D., Nukaga, S., Miyawaki, M., Kawada, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5887 · Cited by 165
Uncommon EGFR mutations in advanced non-small cell lung cancer
O'Kane, G. M., Bradbury, P. A., Feld, R. D., Leighl, N. B., Liu, G., Pisters, K.-M., Kamel‐Reid, S., Tsao, M., & Shepherd, F. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.016 · Cited by 165
Jia, Y., Li, X., Jiang, T., Zhao, S., Zhao, C., Zhang, L., Liu, X., Shi, J., Qiao, M., Luo, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32191 · Cited by 164
ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface
Berger, M. B., Mendrola, J. M., & Lemmon, M. A. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.06.014 · Cited by 164
Memon, A. A., Jakobsen, S., Dagnæs‐Hansen, F., Sørensen, B. S., Keiding, S., & Nexø, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3118 · Cited by 161
Singh, R. R., Kunkalla, K., Qu, C., Schlette, E. J., Neelapu, S. S., Samaniego, F., & Vega, F. (2011) · Oncogene · doi:10.1038/onc.2011.195 · Cited by 161
Molecular Diagnostics in Clinical Oncology
Соколенко, А. П., & Имянитов, Е. Н. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00076 · Cited by 154
Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2300 · Cited by 150
Fassunke, J., Müller, F., Keul, M., Michels, S. Y. F., Dammert, M. A., Schmitt, A., Plenker, D., Lategahn, J., Heydt, C., Brägelmann, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07078-0 · Cited by 150
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149
Hua, F., Li, K., Yu, J.-J., Lv, X.-X., Yan, J., Zhang, X.-W., Sun, W., Lin, H., Shang, S., Wang, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8951 · Cited by 141
Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression
Koo, T., Yoon, A. R., Cho, H., Bae, S., Yun, C., & Kim, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx490 · Cited by 134
Roengvoraphoj, M., Tsongalis, G. J., Dragnev, K. H., & Rigas, J. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.001 · Cited by 131
Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC
Che, T.-F., Lin, C.-W., Wu, Y.-Y., Chen, Y., Han, C., Chang, Y., Wu, C., Hsiao, T.-H., Hong, T.-M., & Yang, P. (2015) · Oncotarget · doi:10.18632/oncotarget.5736 · Cited by 129
Gristina, V., Malapelle, U., Galvano, A., Pisapia, P., Pepe, F., Rolfo, C. D., Tortorici, S., Bazan, V., Troncone, G., & Russo, A. D. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101994 · Cited by 129
Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity
Liu, Y., Li, Z., Zhang, M., Zhou, H., Wu, X., Zhong, J., Xiao, F., Huang, N., Yang, X., Zeng, R., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa279 · Cited by 127
EGFR Blockade Enriches for Lung Cancer Stem–like Cells through Notch3-Dependent Signaling
Arasada, R. R., Amann, J. M., Rahman, M. A., Huppert, S. S., & Carbone, D. P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3724 · Cited by 124
Wang, R., Chen, L., Chen, H., Hu, L., Li, L., Sun, H., Jiang, F., Zhao, J., Liu, G., Tang, J. P., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.009 · Cited by 123
Eskilsson, E., Røsland, G. V., Talasila, K. M., Knappskog, S., Keunen, O., Sottoriva, A., Foerster, S., Solecki, G. M., Taxt, T., Jiřík, R., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now113 · Cited by 122
TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target
Yu, J., Zhou, D., Yang, X., Cui, B., Tan, F., Wang, J., Li, K., Shang, S., Zhang, C., Lv, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17385-0 · Cited by 122
Epidermal growth factor receptor expression in human lung cancer cell lines
Medicine, I. (1989) · Lung Cancer · doi:10.1016/0169-5002(89)90348-6 · Cited by 121
Bahce, I., Smit, E. F., Lubberink, M., van der Veldt, A. A. M., Yaqub, M. M., Windhorst, A. D., Schuit, R. C., Thunnissen, E., Heideman, D. A. M., Postmus, P. E., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0289 · Cited by 121
Liu, L., Qiu, M., Tan, G., Liang, Z., Qin, Y., Chen, L., Chen, H., & Liu, J. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0305-z · Cited by 121
RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus
Huo, L., Wang, Y., Xia, W., Hsu, S.-C., Lai, C., Li, L., Chang, W., Wang, Y., Hsu, M., Yu, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000743107 · Cited by 118
Li, H., Huang, Y. Q., Jiang, D., Cui, L., He, Z., Wang, C., Zhang, Z., Zhu, H., Ding, Y., Li, L., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0238-6 · Cited by 117
Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
Shen, H., Zhu, F., Liu, J., Xu, T., Pei, D., Wang, R., Qian, Y., Li, Q., Wang, L., Shi, Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103305 · Cited by 116
Floc'h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, M. R. V., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0758 · Cited by 115
ErbB4/HER4: Role in Mammary Gland Development, Differentiation and Growth Inhibition
Muraoka-Cook, R. S., Feng, S.-M., Strunk, K. E., & Earp, H. S. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9080-x · Cited by 115
Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens
Querings, S., Altmüller, J., Ansén, S., Zander, T., Seidel, D., Gabler, F., Peifer, M., Markert, E., STEMSHORN, K. C., Timmermann, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019601 · Cited by 115
Luo, Y., Luo, L., Wampfler, J. A., Wang, Y., Liu, D., Chen, Y.-M., Adjei, A. A., Midthun, D. E., & Yang, P. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30329-8 · Cited by 114
Dhillon, S. (2021) · Drugs · doi:10.1007/s40265-021-01533-x · Cited by 113
Brown, B. P., Zhang, Y., Westover, D., Yan, Y., Qiao, H., Huang, V., Du, Z., Smith, J. A., Ross, J. S., Miller, V. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3829 · Cited by 112
The ERBB network facilitates KRAS-driven lung tumorigenesis
Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2565 · Cited by 111
Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110
Yamada, T., Hirai, S., Katayama, Y., Yoshimura, A., Shiotsu, S., Watanabe, S., Kikuchi, T., Hirose, K., Kubota, Y., Chihara, Y., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2037 · Cited by 110
Gao, Y., Fan, X., Li, W., Wei, P., Deng, Y. L., & Fu, X. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.073 · Cited by 108
Azuma, K., Kawahara, A., Sonoda, K., Nakashima, K., Tashiro, K., Watari, K., Izumi, H., Kage, M., Kuwano, M., Ono, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1866 · Cited by 108
Yonesaka, K., Tanizaki, J., Maenishi, O., Haratani, K., Kawakami, H., Tanaka, K., Hayashi, H., Sakai, K., Chiba, Y., Tsuya, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3359 · Cited by 108
Yue, J., Lv, D., Wang, C., Li, L., Zhao, Q., Chen, H., & Xu, L. (2018) · Oncogene · doi:10.1038/s41388-018-0276-2 · Cited by 107
Jackman, D. M., Cioffredi, L. A., Jacobs, L., Sharmeen, F., Morse, L. K., Lucca, J. V., Plotkin, S. R., Marcoux, P. J., Rabin, M. S., Lynch, T. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2886 · Cited by 105
Chung, F., Lee, K., Wang, C., Heh, C., Chan, Y., Chen, H., Kuo, C.-H. S., Feng, P., Lin, T., Wang, C., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27403 · Cited by 104
Ligand-Independent Activation of the EGFR by Lipid Raft Disruption
Lambert, S., Vind-Kezunovic, D., Karvinen, S., & Gniadecki, R. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700168 · Cited by 104
Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Gibbons, D. L., Fossella, F. V., Lam, V. K. L., Patel, A. B., Negrao, M. V., Le, X., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01113 · Cited by 104
Yamada, T., Matsumoto, K., Wang, W., Li, Q., Nishioka, Y., Sekido, Y., Sone, S., & Yano, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1204 · Cited by 103
Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Hirsh, V., Blais, N., Burkes, R. L., Verma, S., & Croitoru, K. (2014) · Current Oncology · doi:10.3747/co.21.2241 · Cited by 103
Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review
Sacher, A. G., Komatsubara, K. M., & Oxnard, G. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.022 · Cited by 103
Optimizing outcomes in EGFR Mutation-Positive Nsclc: Which Tyrosine Kinase Inhibitor and When?
Girard, N. (2018) · Future Oncology · doi:10.2217/fon-2017-0636 · Cited by 103
Yonesaka, K., Takegawa, N., Watanabe, S., Haratani, K., Kawakami, H., Sakai, K., Chiba, Y., Maeda, N., Kagari, T., Hirotani, K., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0517-4 · Cited by 103
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer
Witkiewicz, A. K., Chung, S., Brough, R., Vail, P. J., Franco, J., Lord, C. J., & Knudsen, E. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.022 · Cited by 101
Vázquez‐Martín, A., Cufí, S., Oliveras‐Ferraros, C., Torres-Garcia, V. Z., Corominas-Faja, B., Cuyàs, E., Bonavia, R., Visa, J., Martín-Castillo, B., Barrajón‐Catalán, E., et al. (2013) · Scientific Reports · doi:10.1038/srep02560 · Cited by 100
Friedmann, B. J., Caplin, M. E., Savic, B., Shah, T., Lord, C. J., Ashworth, A., Hartley, J. A., & Hochhauser, D. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0239 · Cited by 100
Yoshida, T., Song, L., Bai, Y., Kinose, F., Li, J., Ohaegbulam, K. C., Muñoz-Antonia, T., Qu, X., Eschrich, S. A., Uramoto, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147344 · Cited by 99
Klughammer, B., Brugger, W., Cappuzzo, F., Ciuleanu, T., Mok, T., Reck, M., Tan, E. H., Delmar, P., Klingelschmitt, G., Yin, A.-Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.107 · Cited by 98
BMI-1, a promising therapeutic target for human cancer
Wang, M., Li, C., Cui, J., Jiao, M., Wu, T., Li, J., & Nan, K. (2015) · Oncology Letters · doi:10.3892/ol.2015.3361 · Cited by 96
Cao, X., Zhu, H., Ali‐Osman, F., & Lo, H. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-26 · Cited by 96
Haura, E. B., Cho, B. C., Lee, J. S., Han, J., Lee, K. H., Sanborn, R. E., Govindan, R., Cho, E. K., Kim, S., Reckamp, K. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9009 · Cited by 96
Zhang, Y., Zeng, Y., Liu, T., Du, W., Zhu, J., Liu, Z., & Huang, J. (2019) · Respiratory Research · doi:10.1186/s12931-019-1137-4 · Cited by 96
Yonesaka, K., Hirotani, K., Kawakami, H., Takeda, M., Kaneda, H., Sakai, K., Okamoto, I., Nishio, K., Janne, P. A., & Nakagawa, K. (2015) · Oncogene · doi:10.1038/onc.2015.142 · Cited by 94
Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer
Baker, A. T., Zlobin, A., & Osipo, C. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00360 · Cited by 94
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Arasada, R. R., Shilo, K., Yamada, T., Zhang, J., Yano, S., Ghanem, R., Wang, W., Takeuchi, S., Fukuda, K., Katakami, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05626-2 · Cited by 93
Heterogeneity and Tumor History
Shibata, D. K. (2012) · Science · doi:10.1126/science.1222361 · Cited by 93
Menéndez, J. A., Vellón, L., & Lupu, R. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.09.027 · Cited by 93
Kim, S., Jang, J.-Y., Koh, J., Kwon, D., Kim, Y. A., Paeng, J. C., Ock, C., Keam, B., Kim, M., Kim, T. M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1407-5 · Cited by 93
Reguart, N., & Remon, J. (2015) · Future Oncology · doi:10.2217/fon.15.15 · Cited by 91
β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations
Nakayama, S., Sng, N., Carretero, J., Welner, R. S., Hayashi, Y., Yamamoto, M., Tan, A. J., Yamaguchi, N., Yasuda, H., Li, D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0184 · Cited by 91
Shaurova, T., Zhang, L., Goodrich, D. W., & Hershberger, P. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00281 · Cited by 89
Minder, P., Zając, E., Quigley, J. P., & Deryugina, E. I. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.002 · Cited by 87
Abhold, E. L., Kiang, A., Rahimy, E., Kuo, S. Z., Wang‐Rodriguez, J., Lopez, J. P., Blair, K. J., Yu, M. A., Haas, M., Brumund, K. T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032459 · Cited by 86
Vasconcelos, P. E. N. S., Gergis, C., Viray, H., Varkaris, A. S., Fujii, M., Rangachari, D., VanderLaan, P. A., Kobayashi, I. S., Kobayashi, S. S., & Costa, D. B. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100051 · Cited by 86
Liu, L., Shao, X., Gao, W., Zhang, Z., Liu, P., Wang, R., Huang, P., Yin, Y., & Shu, Y. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08741.x · Cited by 85
Re, M. D., Tiseo, M., Bordi, P., D’Incecco, A., Camerini, A., Petrini, I., Lucchesi, M., Inno, A., Spada, D., Vasile, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6957 · Cited by 85
Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045
Zhao, P., Yao, M.-Y., Zhu, S., Chen, J., & Yun, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.154 · Cited by 85
C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
Grabe, T., Lategahn, J., & Rauh, D. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00314 · Cited by 84
Zhang, W. C., Wells, J. M., Chow, K.-H., Huang, H., Yuan, M., Saxena, T., Melnick, M. A., Politi, K. A., Asara, J. M., Costa, D. B., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0052-9 · Cited by 84
A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors
El–Gamal, M. I., Mewafi, N. H., Abdelmotteleb, N. E., Emara, M. A., Tarazi, H., Sbenati, R. M., Madkour, M. M., Zaraei, S., Shahin, A. I., & Anbar, H. S. (2021) · Molecules · doi:10.3390/molecules26237376 · Cited by 84
Dong, J., Zhang, R. Y., Sun, N., Smalley, M. D., Wu, Z., Zhou, A., Chou, S.-J., Yu, J.-J., Yang, P., Bao, L., et al. (2019) · ACS Applied Materials and Interfaces · doi:10.1021/acsami.9b01406 · Cited by 83
Zhou, J., Wang, J., Zeng, Y., Zhang, X., Hu, Q., Zheng, J., Chen, B., Xie, B., & Zhang, W. (2015) · Oncotarget · doi:10.18632/oncotarget.6293 · Cited by 82
Knebel, F. H., Bettoni, F., Shimada, A. K., Cruz, M., Alessi, J. V., Negrao, M. V., Reis, L. F. L., Katz, A., & Camargo, A. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.004 · Cited by 82
Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt
Xiong, W., Sun, K.-Y., Zhu, Y., Zhang, X.-Q., Zhou, Y.-H., & Zou, X. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04235-0 · Cited by 82
Chen, Z., Feng, J., Saldivar, J.-S., Gu, D., Bockholt, A., & Sommer, S. S. (2008) · Oncogene · doi:10.1038/onc.2008.71 · Cited by 81
High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?
Ye, X., Zhu, Z.-Z., Zhong, L., Lu, Y., Sun, Y., Yin, X., Yang, Z., Zhu, G., & Ji, Q. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f691f · Cited by 79
Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer
Baik, C. S., Chamberlain, M. C., & Chow, L. Q. M. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000615 · Cited by 78
Zhu, V. W., Klempner, S. J., & Ou, S. I. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.008 · Cited by 78
Lung Tumor Suppressor GPRC5A Binds EGFR and Restrains Its Effector Signaling
Zhong, S., Yin, H., Liao, Y., Yao, F., Li, Q., Zhang, J., Jiao, H., Zhao, Y., Xu, D., Liu, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2005 · Cited by 77
Wu, S., Chang, Y., Hsu, Y.-C., Wu, J., Yang, C.-H., Yu, C., Tsai, M., Shih, J., & Yang, P. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0093 · Cited by 77
The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family
Kennedy, S. P., Hastings, J. F., Han, J. Z. R., & Croucher, D. R. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00088 · Cited by 77
York, E. R., Varella-Garcia, M., Bang, T. J., Aisner, D. L., & Camidge, D. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.02.020 · Cited by 76
Thomasson, M., Hedman, H., Guo, D., Ljungberg, B., & Henriksson, R. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601208 · Cited by 75
Nilsson, M. B., Robichaux, J. P., Herynk, M. H., Cascone, T., Le, X., Elamin, Y. Y., Patel, S. A., Zhang, F., Xu, L., Hu, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.022 · Cited by 75
Jakobsen, K. R., Demuth, C., Madsen, A. T., Hussmann, D., Vad‐Nielsen, J., Nielsen, A. L., & Sørensen, B. S. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.17 · Cited by 74
Leighl, N. B., Karaseva, N. A., Nakagawa, K., Cho, B. C., Gray, J. E., Hovey, T., Walding, A., Rydén, A., & Novello, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.006 · Cited by 74
Goldkorn, T., & Filosto, S. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0220rt · Cited by 73
Kuiper, J. L., Hashemi, S. M. S., Thunnissen, E., Snijders, P. J. F., Grünberg, K., Bloemena, E., Sie, D., Postmus, P. E., Heideman, D. A. M., & Smit, E. F. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.372 · Cited by 73
Bai, X., Zhang, X., Yang, S., An, S., Chen, Z., Su, J., Xie, Z., Gou, L.-Y., & Wu, Y.-L. L. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149370 · Cited by 72
Costa, D. B. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.04 · Cited by 71
In-Depth Analysis Shows Synergy between Erlotinib and miR-34a
Zhao, J. Y., Kelnar, K., & Bader, A. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089105 · Cited by 71
Bollu, L. R., Ren, J., Blessing, A. M., Katreddy, R. R., Gao, G., Xu, L., Wang, J., Su, F., & Weihua, Z. (2014) · Cell Cycle · doi:10.4161/cc.29338 · Cited by 71
Li, L., Wang, Y., Jiao, L., Lin, C., Lu, C., Zhang, K., Hu, C., Ye, J., Zhang, D., Wu, H., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.027 · Cited by 67
Tian, Y., Zhang, Z., Miao, L., Yang, Z., Yang, J., Wang, Y., Qian, D., Cai, H., & Wang, Y. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14648701447814 · Cited by 65
Lum, L. G., Thakur, A. B., Choi, M., Deol, A., Kondadasula, S. V., Schalk, D. L., Fields, K., Dufrense, M., Philip, P., Dyson, G. E., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1773201 · Cited by 64
Zhang, Y., Zhang, Y., Niu, W., Ge, X., Huang, F., Pang, J., Li, X., Wang, Y., Gao, W., Fan, F., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.750031 · Cited by 63
Epidermal growth factor receptor expression status in lung cancer correlates with its mutation
Suzuki, M., Shigematsu, H., Hiroshima, K., Iizasa, T., Nakatani, Y., Minna, J. D., Gazdar, A. F., & Fujisawa, T. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.08.007 · Cited by 62
Lee, C., Lai, T., Tsai, M., Chang, Y., Ho, Y.-H., Yu, I., Yeh, T.-W., Chou, C.-C., Lin, Y.-S., Lawrence, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms15502 · Cited by 62
Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer
Ma, S., Zhang, L., Ren, Y., Dai, W., Chen, T., Luo, L., Zeng, J., Mi, K., Lang, J., & Cao, B. (2021) · Oncogene · doi:10.1038/s41388-021-01734-4 · Cited by 62
Ettenberg, S. A., Rubinstein, Y., Banerjee, P., Nau, M. M., Keane, M., & Lipkowitz, S. (1999) · Molecular Cell Biology Research Communications · doi:10.1006/mcbr.1999.0157 · Cited by 61
Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer
Nie, K., Jia, Y., & Zhang, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-2758-3 · Cited by 61
Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer
Matsuda, N., Lim, B., Wang, X., & Ueno, N. T. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1299707 · Cited by 60
Ruan, Z., & Kannan, N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803152115 · Cited by 60
Chang, L., Fang, S.-R., Chen, Y.-B., Yang, Z.-H., Yuan, Y., Zhang, J., Ye, L., & Gu, W. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1058-8 · Cited by 60
Zeng, L., Yang, N., & Zhang, Y. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.005 · Cited by 59
Wang, X., Zhou, L., Yin, J. C., Wu, X., Shao, Y. W., & Gao, B. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.015 · Cited by 58
Masuzawa, K., Yasuda, H., Hamamoto, J., Nukaga, S., Hirano, T., Kawada, I., Naoki, K., Soejima, K., & Betsuyaku, T. (2017) · Oncotarget · doi:10.18632/oncotarget.22297 · Cited by 57
Hellyer, J. A., Stehr, H., Das, M. S., Padda, S. K., Ramchandran, K. J., Neal, J. W., Diehn, M., & Wakelee, H. A. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.002 · Cited by 56
Yao, W., Wang, L., Huang, H., Li, X., Wang, P., Mi, K., Cheng, J. Z., Liu, H., Gu, C., Huang, L., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06818-0 · Cited by 56
Regulation of EGFR Protein Stability by the HECT-type Ubiquitin Ligase SMURF2
Ray, D., Ahsan, A., Helman, A., Chen, G., Hegde, A., Ramanand, S. G., Zhao, L., Kiyokawa, H., Beer, D. G., Lawrence, T. S., et al. (2011) · Neoplasia · doi:10.1593/neo.11632 · Cited by 55
Ali, A., Levantini, E., Fhu, C. W., Teo, J. T., Clohessy, J. G., Goggi, J., Wu, C.-S., Chen, L., Chin, T. M., & Tenen, D. G. (2019) · Theranostics · doi:10.7150/thno.35805 · Cited by 55
Self-citationwritten on behalf of AME Lung Cancer Cooperative Group, Liang, H., Pan, Z., Wang, W., Guo, C., Chen, D., Zhang, J., Zhang, Y., Tang, S., He, J., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.150 · Cited by 54
Togashi, Y., Hayashi, H., Terashima, M., Velasco, M. A. D., Sakai, K., Fujita, Y., Tomida, S., Nakagawa, K., & Nishio, K. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000353 · Cited by 53
Passarelli, A. M., Aieta, M., Sgambato, A., & Gridelli, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01479 · Cited by 53
Hisakane, K., Seike, M., Sugano, T., Yoshikawa, A., Matsuda, K., Takano, N., Takahashi, S., Noro, R., & Gemma, A. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13943 · Cited by 51
MiR-130a Overcomes Gefitinib Resistance by Targeting Met in Non-Small Cell Lung Cancer Cell Lines
Zhou, Y., Liu, J., & Sun, W. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.3.1391 · Cited by 50
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression
Yong, K. J., Bassères, D. S. D. S., Welner, R. S., Zhang, W. C., Yang, H. H., Yan, B., Alberich-Jordà, M., Zhang, J., de Figueiredo‐Pontes, L. L., Battelli, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6066 · Cited by 50
Self-citationWu, K., Li, J., Qi, Y., Zhang, C., Zhu, D., Liu, D., & Zhao, S. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108995 · Cited by 50
Peng, L., Song, Z.-G., & Jiao, S.-C. (2014) · Scientific Reports · doi:10.1038/srep06104 · Cited by 48
Nishimura, Y., Yoshioka, K., Bereczky, B., & Itoh, K. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-42 · Cited by 48
Terp, M. G., Jacobsen, K., Molina‐Vila, M. Á., Karachaliou, N., Beck, H. C., Bertrán-Alamillo, J., Giménez-Capitán, A. A., Cardona, A. F., Rosell, R., & Ditzel, H. J. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00208-w · Cited by 48
Liu, Y., Tsai, M., Wu, S., Chang, T., Tsai, T.-H., Gow, C., Wang, H., & Shih, J. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.09.015 · Cited by 47
Chang, C. C., Yang, M.-H., Lin, B.-R., Chen, S.-T., Pan, S.-H., Hsiao, M., Lai, T.-C., Lin, S.-K., Jeng, Y., Chu, C.-Y., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.136 · Cited by 46
Dziadziuszko, R., Holm, B., Skov, B. G., Østerlind, K., Sellers, M. V., Franklin, W. A., Bunn, P. A., Varella‐Garcia, M., & Hirsch, F. R. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl407 · Cited by 46
Yadollahi, P., Jeon, Y., Ng, W. L., & Choi, I. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.241 · Cited by 46
Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
Wang, J., Li, X., Xue, X., Ou, Q., Wu, X., Liang, Y., Wang, X., You, M., Shao, Y. W., Zhang, Z., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31895 · Cited by 45
The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine
Passarelli, A. M., Tucci, M., Mannavola, F., Felici, C., & Silvestris, F. (2019) · Tumor Biology · doi:10.1177/1010428319837138 · Cited by 45
Si, J., Ma, Y., Bi, J., Xiong, Y., Lv, C., Li, S., Wu, N., & Yang, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1486-3 · Cited by 45
Cucchiara, F., Re, M. D., Valleggi, S., Romei, C., Petrini, I., Lucchesi, M., Crucitta, S., Rofi, E., LIPERI, A. D., Chella, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.593831 · Cited by 45
Wu, J.-Y., & Shih, J.-Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s118071 · Cited by 44
Peter, Y., Comellas, A. P., Levantini, E., Ingenito, E. P., & Shapiro, S. D. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20485 · Cited by 44
Self-citationResponse to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma
Piotrowska, Z., Fintelmann, F. J., Sequist, L. V. D., & Jahagirdar, B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.017 · Cited by 44
Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations
Lee, Y., Kim, T. M., Kim, D., Kim, S., Kim, M., Keam, B., Ku, J., & Heo, D. S. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.006 · Cited by 44
Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer
Имянитов, Е. Н., Демидова, И. А., Gordiev, M., Филипенко, М. Л., Kekeeva, T. V., Moliaka, Y. K., Анатольевна, Г. П., Kozhemyako, V. B., Vodolazhskiy, D. I., Sergeyeva, L. A., et al. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0213-4 · Cited by 43
Ribeiro, M. F. S. A., Knebel, F. H., Bettoni, F., Saddi, R., Sacardo, K. P., Canedo, F. S. N. A., Alessi, J. V. M., Shimada, A. K., Marin, J. F. G., Camargo, A. A., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00149-4 · Cited by 43
Cucchiara, F., Petrini, I., Romei, C., Crucitta, S., Lucchesi, M., Valleggi, S., Scavone, C., Capuano, A., LIPERI, A. D., Chella, A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105643 · Cited by 43
Baik, C. S., Wu, D., Smith, C., Martins, R. G., & Pritchard, C. C. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000586 · Cited by 42
Re, M. D., Bordi, P., Rofi, E., Restante, G., Valleggi, S., Minari, R., Crucitta, S., Arrigoni, E., Chella, A., Morganti, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0238-z · Cited by 42
Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles
Zanetti-Domingues, L. C., Bonner, S. E., Martin-Fernandez, M. L., & Huber, V. (2020) · Cells · doi:10.3390/cells9112505 · Cited by 41
Programmed death-ligand 1 expression and T790M status in EGFR -mutant non-small cell lung cancer
Hata, A., Katakami, N., Nanjo, S., Okuda, C., Kaji, R., Masago, K., Fujita, S., Yoshida, H., Zama, K., Imai, Y., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.022 · Cited by 40
A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells
Dimri, M., Kang, M., & Dimri, G. P. (2016) · Oncotarget · doi:10.18632/oncotarget.8811 · Cited by 37
Oxnard, G. R., Cantarini, M., Frewer, P., Hawkins, G., Peters, J., Howarth, P., Ahmed, G. F., Sahota, T., Hartmaier, R. J., Li-Sucholeiki, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps9119 · Cited by 37
Ebert, E. B. F., McCulloch, T., Hansen, K. H., Linnet, H., Sørensen, B. S., & Meldgaard, P. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.016 · Cited by 37
Codony‐Servat, J., García-Román, S., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Giménez-Capitán, A. A., Viteri, S., Cardona, A. F., d'Hondt, E., Karachaliou, N., & Rosell, R. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.030 · Cited by 36
Chang, L.-C., Lim, C., Chang, L., Chen, K., Shih, J., & Yu, C. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.025 · Cited by 36
Tang, X., Li, Y., Yan, W., Qian, W., Pang, T., Gong, Y., & Yang, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719919 · Cited by 36
Nivolumab in non-small-cell lung cancer with EGFR mutation
Yoshida, H., Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Tsuji, T., Nomizo, T., Yasuda, Y., Funazo, T. Y., & Hirai, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx745 · Cited by 35
Re, M. D., Petrini, I., Mazzoni, F., Valleggi, S., Gianfilippo, G., Pozzessere, D., Chella, A., Crucitta, S., Rofi, E., Restante, G., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.10.003 · Cited by 31
let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer
Yin, J., Hu, W., Pan, L., Fu, W., Dai, L., Jiang, Z., Zhang, F., & Zhao, J. (2019) · Oncology Reports · doi:10.3892/or.2019.7197 · Cited by 30
Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation
Erdem‐Eraslan, L., Gao, Y., Kloosterhof, N. K., Atlasi, Y., Demmers, J., Sacchetti, A., Kros, J. M., Smitt, P. A. E. S., Aerts, J. G. J. V., & French, P. J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.02.006 · Cited by 29
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
Maroni, G., Bassal, M. A., Krishnan, I., Fhu, C. W., Savova, V., Žilionis, R., Maymi, V. A., Pandell, N., Csizmadia, E., Zhang, J., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01897-6 · Cited by 29
Self-citationShen, C.-H., Chou, C.-C., Lai, T., Hsu, J.-E., Lin, Y.-S., Liu, H., Chen, Y.-K., Ho, I.-L., Hsu, P., Chuang, T., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.642625 · Cited by 29
Huang, X., Sun, Y., Tan, M., Ma, W., Gao, P., Lin, Q., Lu, J., Yang, Y., Wang, K., Chen, W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.772770 · Cited by 29
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib
Saxon, J. A., Sholl, L. M., & Janne, P. A. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.006 · Cited by 28
Janne, P. A., Baik, C. S., Su, W., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9007 · Cited by 27
Yu, W., Ye, F., Yuan, X., Ma, Y., Mao, C., Li, X., Li, J., Dai, C., Qian, F.-H., Li, J., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08590-1 · Cited by 27
Chung, C., Yoo, G., Kim, T., Lee, D., Lee, C. S., Cha, H. R., Park, Y., Moon, J. Y., Jung, S. S., Kim, J. O., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.111 · Cited by 26
Therapeutic applications of CRISPR RNA-guided genome editing
Koo, T., & Kim, J. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw032 · Cited by 26
Wong, K. (2008) · Lung Cancer · doi:10.1016/s0169-5002(08)70100-4 · Cited by 24
Ho, Y. S., Yip, L. Y., Basri, N. B., Chong, V. S. H., Teo, C. C., Tan, E., Lim, K. L., Tan, G. S., Yang, X., Yeo, S. Y., et al. (2016) · Scientific Reports · doi:10.1038/srep35110 · Cited by 24
Re, M. D., Rofi, E., Cappelli, C., Puppo, G., Crucitta, S., Valleggi, S., Chella, A., Danesi, R., & Petrini, I. (2019) · BMC Cancer · doi:10.1186/s12885-019-5604-6 · Cited by 24
Bennouna, J., Girard, N., Audigier-Valette, C., Thuaut, A. L., Gervais, R., Masson, P., Marcq, M., Molinier, O., Cortot, A. B., Debieuvre, D., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.09.007 · Cited by 24
Udagawa, H., Umemura, S., Murakami, I., Mimaki, S., Makinoshima, H., Ishii, G., Miyoshi, T., Kirita, K., Matsumoto, S., Yoh, K., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.014 · Cited by 23
Coleman, N., Woolf, D., Welsh, L. C., McDonald, F., MacMahon, S., Yousaf, N., & Popat, S. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.006 · Cited by 23
Little, A. C., Hristova, M., van Lith, L., Schiffers, C., Dustin, C. M., Habibovic, A., Danyal, K., Heppner, D. E., Lin, M.-C. J., van der Velden, J. L. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41395-8 · Cited by 22
Chen, J. A., & Riess, J. W. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.32 · Cited by 22
Targeting microtubule sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
Chin, T., Gandhi, T. K. B., Man, E. P. S., Clohessy, J. G., Csizmadia, E., Quinlan, M. P., Putti, T. C., Wan, S., Xie, C., Ali, A., et al. (2020) · Theranostics · doi:10.7150/thno.38729 · Cited by 21
Self-citationYiming, R., Takeuchi, Y., Nishimura, T., Li, M., Wang, Y., Meguro‐Horike, M., Kohno, T., Horike, S., Nakata, A., & Gotoh, N. (2021) · Cancer Science · doi:10.1111/cas.15036 · Cited by 20
Pal, D., Tepeš, P. Š., Lindsted, T., Ibarra, I., Lujambio, A., Sabinina, V. J., Şentürk, Ş., Miller, M., Korimerla, N., Huang, J., et al. (2021) · eLife · doi:10.7554/elife.66109 · Cited by 16
Qu, F., Zhou, Y., & Yu, W. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001242 · Cited by 16
Re, M. D., Bordi, P., Petrini, I., Rofi, E., Mazzoni, F., Belluomini, L., Vasile, E., Restante, G., Costanzo, F. D., Falcone, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20947 · Cited by 15
Ma, Z., Lu, S., Zhou, H., Zhang, S., Wang, Y., & Lin, N. (2020) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.8955 · Cited by 15
Cited by
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
Metadata
- Authors
- Levantini, E., Maroni, G., Del Re, M., & Tenen, D. G.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 85
- Pages
- 253-275
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W4223622421
- Cited by
- 356
- References
- 410
- FWCI
- 38.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.